PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC)
Clinical trials for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC) explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC) trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat ovarian cancer: first patients sought for experimental injection
Disease control Not yet recruitingThis is a first-in-human study to test the safety and find the right dose of an experimental drug called WSK-IM02 for women with recurrent ovarian cancer that has stopped responding to platinum-based chemotherapy. The study will enroll up to 36 participants who will receive the d…
Matched conditions: PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC)
Phase: PHASE1 • Sponsor: WestVac Biopharma Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for women with aggressive ovarian cancer: testing a powerful drug duo
Disease control Not yet recruitingThis study is testing a new two-drug combination for women whose ovarian cancer has returned and stopped responding to standard platinum-based chemotherapy. It will enroll about 30 participants to see if combining an antibody-drug conjugate (sacituzumab tirumotecan) with an exist…
Matched conditions: PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (PROC)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Feb 25, 2026 15:06 UTC